Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Achillion Pharma Shares Slide

By Pharmaceutical Processing | July 2, 2013

Shares of Achillion Pharmaceuticals sank Tuesday before markets opened and a day after the drug developer said federal regulators placed a hold on an early-stage study of a drug combination involving its potential hepatitis C treatment sovaprevir.

Hepatitis C has become a major area of drug research because it is a chronic illness and more cases are expected to be diagnosed as Baby Boomers age. Companies are racing to develop new and more convenient treatments.

The New Haven, Conn., company said Monday shortly after markets closed that the Food and Drug Administration placed a clinical hold on the study after researchers saw an unanticipated elevation in liver enzymes in several subjects.

Achillion was studying the effects of administering sovaprevir with ritonavir-boosted atazanivir when researchers detected the unexpected elevations, stopped administering the combination and contacted the FDA.

The FDA has asked for reports from some drug interaction studies and a safety analysis of on-going sovaprevir studies. Achillion said it expects to provide that information in about six weeks.

Meanwhile, regulators will allow the continued enrollment and treatment of patients in a mid-stage study of sovaprevir.

Achillion currently is studying three potential treatments for chronic hepatitis C, and sovaprevir is one of its most advanced candidates. The company expects to report some results from that study in the third quarter.

Hepatitis C is a virus that can lead to life-threatening liver damage and is the main cause of liver transplants in the United States. The disease is spread through the blood, and that can happen through sharing intravenous drug needles or having sex with an infected person. It can go undetected for many years until the liver is severely damaged.

Achillion shares sank more than 23 percent, or $1.98, to $6.38 in premarket trading Tuesday about 90 minutes ahead of the market opening. Its shares have traded in a 52-week range of $5.42 to $11.36.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE